Wall Street analyst estimates for Apimeds Pharmaceuticals US, Inc (APUS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-14 | $-11.77 | ||
| 2026-05-26 | $-22.60 | ||
| 2025-11-12 | $-0.14 | ||
| 2025-08-19 | $-0.26 | ||
| 2025-05-19 | $-0.35 |
Valuation Ratios
| Price / Book | 0.02 |
| EV / EBITDA | -0.33 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | $5706 |
| Gross Profit | 0 | 0 | 0 | 0 | -$5706 |
| Research & Development | $489939 | $368000 | $98544 | 0 | $1.6M |
| Selling, General & Admin | $529555 | $271529 | $648892 | $1.3M | $10.3M |
| Operating Expenses | $1.0M | $639529 | $747436 | $1.3M | $11.9M |
| Operating Income | -$1.0M | -$639529 | -$747436 | -$1.3M | -$11.9M |
| EBITDA | -$1.0M | -$639529 | -$739625 | -$1.3M | -$5.7M |
| Interest Expense | $6740 | $29137 | $38069 | $117719 | $283011 |
| Pre-tax Income | -$1.0M | -$668666 | -$777694 | -$1.4M | -$6.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$1.0M | -$668666 | -$777694 | -$1.4M | -$6.0M |
| EPS | $-8.90 | $-5.80 | $-6.75 | $-12.00 | $-5.50 |
| EPS (Diluted) | $-8.08 | $-5.27 | $-6.13 | $-11.00 | $-5.50 |
| Shares Outstanding (Diluted) | $126934 | $126934 | $126934 | $126934 | $1.1M |
Price
| Price | $1.60 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Related companies: ANTX · IGC · MIRA · MLSS · MYO · NXTC · POCI
Explore sector: Healthcare · Biotechnology
More sections of APUS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks